Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
FAR OUT!! EOD 300,000 and .05
That's no little EOD paint job!
What does that buyer know that we do not?
"hmmmm .05 on the ask....
Any of the naysayers want to take a guess why the stock is looking at .05 with no news?"
------------------------------------------------------------
Well es1, I am nobodies naysayer here but my guess on why the pps pressure is positive would be that Kim has made several positive pivots to the business plan in light of the delay in Vietnam. Maybe plan B and C ,what ever they may be, are moving forward now along with the delayed plan A. He has assembled a strong team and recently added specific talent to begin to kick ass and tear the roof of the sucker! I feel that KBLB if finally on that launch pad we have been talking about for years.
Basic background weekend homework for KBLB investors: http://www.ted.com/talks/david_bolinsky_animates_a_cell#t-78864
One of these days the rest of the world will catch up with those of us who are early bird longs. Hang in there boys and girlzzz. If I did not have to stroke a big check to Uncle Sam right now I would be buying big down here...
Keep ON Smiling
Blue Sky and Good Air,
The King ;)
http://www.articlesbase.com/business-articles/what-makes-spider-silk-a-suitable-option-for-commercial-use-7246381.html
What Happens in Lansing Stays in Lansing
I'll give you that.
Wish that had been me making that big "Monster" buy today! Hopefully they know something that is going on that I don't.
Maybe there was a 3rd party verification attempted and they did not publish because the results sucked. :)
http://www.materials360online.com/newsDetails/52517
Bio Focus: Spinning artificial spider silk remains a challenge
Laurel Hamers
Materials Research Society/MRS Bulletin | Published: 19 March 2015
shutterstock-220 Image via Shutterstock.com. Click image to enlarge.
Although spider webs can be torn apart with one well-aimed sweep of a broom, the silk that forms them is, by weight, one of the strongest materials found in nature. It’s also lightweight, biodegradable, sticky, and slightly stretchy—all properties that make it desirable for a variety of applications.
Humans have been collecting silk from silkworm colonies for thousands of years to create textiles. However, using the same strategy to harvest natural spider silk—which is stronger and lighter than that of silkworms—isn’t a practical option.
Spiders can become territorial and even cannibalistic when kept in close proximity to each other, and the labor required to harvest their silk is too great to make the process commercially viable. Instead, scientists are studying the molecular basis for spider silk’s valuable properties with the hopes of eventually creating a commercially viable biomimetic synthetic silk fiber.
“One of the main obstacles to synthesizing true, biomimetic spider silks was, and still is, a lack of understanding about the natural material and processes by which it is created,” said Cameron Brown of the University of Oxford and an author of a review paper on synthetic silk in the January 14 issue of the Journal of Materials Research. “We are getting much better at making proteins similar to the natural proteins, yet our processing capabilities lag behind.”
The two main proteins believed to be responsible for silk production are large molecules called Spidroins, but over a hundred secondary proteins might help finesse the silk’s properties. Researchers have turned to a variety of organisms, from bacteria to goats, to recombinantly express these relevant proteins. None, however, has yielded synthetic fibers on par with natural ones in strength. Recombinant silk protein expression has suffered from low protein yield—making the process inefficient—and low molecular weight, weakening the resulting product. It seems that while spiders are well suited to efficiently express these large proteins critical to their survival, other species are not.
Scientists at Utah State University turned to silkworms as an alternative, engineering them to create a hybrid spider-silkworm protein. “This was a great idea, as most expression systems aren’t well suited to making proteins of the size of the main silk proteins,” said Federico Rosei, a researcher at INRS University in Quebec, Canada, and another contributor to the review.
Once the proteins are expressed, the resulting slurry must be spun into a thread. Spiders have specialized equipment for this task: glands in the abdomen release a molten protein mixture, which flows through ducts that reorder the proteins into a fiber before releasing it through spinnerets. For humans, it has proven to be more of a challenge. One promising solution uses microfluidics, where fiber assembly takes place at the interface of a fluid protein stream and a water-insoluble liquid like oil.
It’s too soon to call spider silk the next miracle material—many of the technologies being developed, though promising, are still in their nascent stages, and the exact properties of a given spider silk depend on the complex interplay between its molecular makeup and the fiber structure. Nevertheless, opportunities for its eventual use abound.
Randy Lewis, a Utah State University researcher who was not involved in the review article but has been studying spider silk for 25 years, points out that the potential for the material goes beyond the strong, lightweight fabrics one might expect. “We have found that we can make a variety of things other than fibers from spider silk,” he says, like adhesives, coatings, and highly absorbent sponges.
The authors of the review agree. “We think some of the most exciting applications aren’t the ones that follow the obvious properties of spider silk—applications in biophotonics and sensing, for example,” said Brown.
Reprinted from MRS Bulletin.
"How do you make a profit when KBLB goes down? "
Some may think that their negativity on message boards could drive the price down for adding shares to sell later for an even greater profit. I don't think that works but this could be the motivation.
Well, I'll give you that saint but we got this guy:
Malcolm J. Fraser, Jr.
Rev. Julius A. Nieuwland, CSC, Professor of Biological Sciences
Ph.D., Ohio State University
Postdoctoral, Penn State University, Texas A & M University
Fellow, American Association for the Advancement of Science
Fellow, Royal Entomological Society
Fellow, Entomological Society of America
Fellow, American Academy of Microbiology
The Fraser laboratory merges research in Molecular Virology and Transgenic Engineering with the particular goals of advancing applications that improve the human condition. A major thrust of the research in this laboratory concerns the utilization of molecular approaches to understanding and manipulating virus genetics in ways that permit beneficial transgenic alteration of the invertebrate hosts of these viruses.
The Home of piggyBac
The Fraser lab has a solid history in the molecular genetics of Baculoviruses, both from the standpoint of their exploitation as expression vectors and as an experimental system for the isolation and analysis of a unique family of Lepidopteran transposons. Our laboratory is responsible for the characterization and development of the piggyBac transposon (http://piggybac.bio.nd.edu), a highly versatile transposon vector with wide utility for transgenic engineering in a host of eukaryotic species. This transposon is now facilitating applications of genetic manipulation and gene characterization for a wide range of important invertebrate species that previously had few genetic tools. Important invertebrate species including the economically significant silkworm, Bombyx mori , and human disease vectors including Aedes aegypti and Anopheles stephensi , may now be transgenically engineered with relative facility, allowing the analysis of gene identity, expression, and function.
PiggyBac has also found utility in mammalian genetic engineering including mouse, rat and porcine animal models, as well as human cells. Most recently, piggyBac has been used in the establishment and differentiation of induced pluripotent stem cells, an important and viable alternative to embryonic stem cells.
Research Emphasis in Molecular Virology
The Molecular Virology aspects of our research include exploring genetic strategies for suppressing vectored virus infections in mosquito cells including the viral disease agents for Dengue Fever, Yellow Fever, West Nile Fever and Chikungunya virus. These are among the most devastating disease agents of humankind. Hepatitis C and HIV are widespread devastating chronic human disease viruses for which a cure has remained elusive. Our approach to inhibiting all of these viruses involves the use of catalytic RNA molecules called Ribozymes. The success of this strategy for antiviral suppression has been remarkable, and may eventually lead to eradication of vectored alphaviruses or flaviruses, and cures for Hepatitis C and HIV/AIDS.
Research Emphasis in Transgenic Engineering
The Invertebrate Transgenesis aspects of our research effort involve applications in significant Lepidopteran and Dipteran insects. Among Lepidopteran insects, we seek to improve caterpillars as bioreactors for the production of human therapeutic gene products. This involves various transgenic approaches that serve to alter properties of the insect systems that limit its utility for these purposes, and enhance those properties that are attractive. Research in this direction involves a significant effort to uncover strategies for optimization and controlled expression of genes in these insect systems.
Among the Dipteran insects, our principal effort involves the development of strategies for transgenic modification of mosquito vectors to reduce their capacity for vectoring human disease agents, particularly Flavivirus disease agents like Dengue Fever Virus. While transposon vectors such as piggyBac remain a significant tool in these transgenesis applications, our lab also explores alternative approaches to effecting transgenesis of these mosquito vectors to provide a versatile “toolbox” for functional genomics in these important disease arthropods. While Drosophila melanogaster is not a focus of our research it remains a significant model genetic system that we utilize to validate our transgenesis approaches prior to testing them in other insect systems.
We also have a vigorous program of research in transgenic silkworms. Silkworms are natural protein biocreators and may be engineered to produce recombinant human diagnostic and therapeutic proteins, as well as recombinant silks. One recent application has been the development of recombinant spider silk production in transgenic silkworms (see: www.kraiglabs.com).
Research Emphasis in Induced Pluripotent Stem Cells
We are taking advantage of piggyBac’s utility in reprogramming cells for pluripotency to develop induced pluripotent stem cell strategies for several neurological disorders. Of principal concern is the Neimann-Pick C type 1 and 2, for which we are using mouse model systems to attempt to develop induced pluripotent stem cell therapies.
Patents:
•U.S. Patent No. 4,870,023. "Recombinant baculovirus occlusion bodies in vaccines and biological control." M. J. Fraser, E. Rosen, and V. Ploplis.American Biogenetics Sciences, Inc.
•U.S. Patent No. 5,041,379. "Heliothis expression systems." M. J. Fraser, E. Rosen, and V. Ploplis. American Biogenetics Sciences, Inc.
•U. S. Patent No. 6,218,185. “The piggyBac Transposon for Transgenic Engineering of Insects.” M. J. Fraser, P. D. Shirk, T. A. Elick, and O. P. Perera.USDA/ARS, University of Florida, and University of Notre Dame.
•U. S. Patent No. 6,551,825. “piggyBac transposon-based genetic transformation system for insects.” P. D. Shirk, M. J. Fraser, T. A. Elick and O. P. Perera. USDA/ARS, University of Florida and University of Notre Dame.
•U. S. Patent No. 6,962,810. “Methods and compositions for transposition using minimal segments of the eukaryotic transformation vector piggyBac.” M. J. Fraser, X. Li. University of Notre Dame.
•U. S. Patent No. 7,105,343. “Methods and compositions for transposition using minimal segments of the eukaryotic transformation vector piggyBac.” M. J. Fraser, X. Li. University of Notre Dame.
•U. S. Patent No. 7,932,088.. “High efficiency transformation of Plasmodium falciparum by the Lepidopteran transposon piggyBac.” J. H. Adams, M. J. Fraser, B. Balu, and D. A. Shoue. University of Notre Dame.
Selected Publications:
M.J. Fraser Jr., L. Carey, K. Boonvisudhi, and H.G.H. Wang. (1995). “Assay for movement of Lepidepteran transposon IFP2 in insect cells using a Baculovirus genome as a target DNA”. Virology 211:397-407.
A.M. Handler, S.D. McCombs, M.J. Fraser, S.J. Saul. (1998). “The lepidopteran transposon vector, piggyBac, mediates germ-line transformation in the Mediterranean fruit fly”. Proc. Natl. Acad. Sci. USA 95:7520-7525.
T. Tamura, C. Thibert, C. Royer, T. Karda, E. Abraham, M. Kamba, N. Komoto, J. Thomas, B. Mauchamp, G. Chavancy, P. Shirk, M.J. Fraser, J. Prudhomme, and P. Couble. (2000). “Germline transformation of the pilleworm Bombyx mori L. using a piggyBac transposon-derived vector”. Nat. Biotech, 18:81-84.
N. Lobo, A. Hua-Van, X. Li, B. M. Nolan and M. J. Fraser. (2002). “Germ live transformation of the yellow fever mosquito, Aedes aegypti, mediated by transpositional insertion of a piggyBc vector”. Ins. Mol. Biol., 11:133-139.
A. Sarkar, C. Sim, Y. S. Hong, J. R. Hogan, M. J. Fraser, H. M. Robertson, F. H. Collins. (2003). “Molecular evolutionary analysis of the widespread piggyBac transposon family and related "domesticated" sequences”. Mol. Gen. Genomics 270:173-180.
X. Li, R. Harrell, A. Handler, T. Beam, K. Hennessy, and M.J. Fraser. (2004). “piggyBac internal sequences are necessary for efficient transformation of target genomes”. Insect Mol. Biol. 14:17-30
B. Balu, D. A. Shoue, M. J. Fraser and J. Adams. (2005). “High efficiency transformation of Plasmodium falciparum by the lepidopteran transposable element piggyBac “. Proc. Natl. Acad. Sci., 102:16391-6.
N. Lobo, T.S. Fraser, J. Adams, and M.J. Fraser. (2006). “Interplasmid transposition demonstrates piggyBac mobility in vertebrate species”. Genetica, 128:347-57.
E.T. Shinohara, J.M. Kaminski, D.J. Segal, P. Pelczar, R. Kolhe, T. Ryan, C.J. Coates, M.J. Fraser, A.M. Handler, R. Yanagimachi, and S. Moisyadi. (2007). “Active integration: new strategies for transgenesis”. Transgenic Res. 16:333-339.
X. Shi, R.L. Harrison, J.R. Hollister, A. Mohammed, M.J. Fraser Jr, and D.L. Jarvis. (2007). “Construction and characterization of new piggyBac vectors for constitutive or inducible expression of heterologous gene pairs and the identification of a previously unrecognized activator sequence in piggyBac”. BMC Biotechnol., 7:5-23.
N. Sethurama, M.J. Fraser, Jr., P. Eggleston, and D A. O’Brochta. (2007). “Post-integration stability of piggyBac in Aedes aegypti”. Insect. Biochem. Mol. Biol. 37:941-951.
J.H. Keith, T.S. Fraser, and M.J. Fraser, Jr. 2008. “Analysis of the piggyBac transposase reveals a functional nuclear targeting signal in the 94 c-terminal residues”. BMC Molec. Biol. 9:72.
J. Keith, C. Schaeper, T. S. Fraser, and M. J. Fraser, Jr. (2008). “Mutational analysis of highly conserved acidic amino acids in the piggyBac transposase”. BMC Mol. Biol. 9:73.
J. Chompoosri, T. Fraser, Y. Rongsriyam, N. Komalamisra, P. Siriyasatien, U. Thavara, A. Tawatsin, and M. J. Fraser, Jr. (2009). “Intramolecular integration assay validates integrase Phi C31 and R4 potential in a variety of insect cells”. Southeast Asian J. Trop. Med. Public Health. 40:1235-1254.
B. Balu, C. Chauhan, S.P. Maher, D. A. Shoue, H. Wang, J. Kissinger, M.J. Fraser Jr. and J.H. Adams. (2009). “Whole-genome mutagenesis of Plasmodium falciparum identifies critical blood-stage genes”. BMC Microbiology, 9:83.
P. Nawtaisong, J. Keith, T. Fraser, V.Balaraman, A. Kolokoltsov, R. Davey, S. Higgs, A. Mohammed, Y. Rongsriyam, N. Komolamisra, M.J. Fraser, Jr.: (2009) “Effective suppression of Dengue fever virus in mosquito cell cultures using retroviral transduction of hammerhead ribozymes targeting the viral genome”. Virology Journal, 6:73. PMID:19497123
A.G. Lynch, F. Tanzer, M.J. Fraser, E.G. Shephard, A.L. Williamson, E.P. Rybicki. (2010). “Use of the piggyBac transposon to create HIV-1 gag transgenic insect cell lines for continuous VLP production”. BMC Biotechnol.10:30.
H.J. Ferguson, L.G. Neven, S.T. Thibault, A. Mohammed, M.J. Fraser. (2010). “Genetic transformation of the codling moth, Cydia pomonella L., with piggyBac EGFP”. Transgenic Res. [Epub ahead of print]
J.R. Carter, J.H. Keith, P.V. Barde, T.S. Fraser, & M.J. Fraser, Jr. (2010) “Targeting of highly conserved Dengue virus sequences with anti-Dengue virustrans-splicing group I introns”. BMC Mol Biol, 11:84. PMID:21078188
Nice buy silk. With any news at all that's even halfway decent we should be able to hold .06.
I think you will be very happy with your 300k addition as the year progresses.
Was a rep of KBLB there?
Good one rayoooooooo
I am thinking the word of the century for KBLB will ultimately be utility. Economists use this term to refer to happiness or satisfaction. :)
I think it will not me long until we are told something good about the company.
Ha ha. I was just kidding 07.
Is this any different that the other bacteria spider goo machines out there?
You are welcome son. ;)
Looks like that's about all there is to that one but I agree with the reference to Kraig.
I am just glad that we have sandals on the ground in Nam. Thanx dad for your solid dd.
I think applications in products being used in human medicine could be sooner than you think. Bandages for example.
http://www.healthydietbase.com/using-spider-webs-to-heal-wounds/
Using Spider Webs to Heal Wounds
January 27, 2015
Did you know spider webs serve another purpose other than being the home of your friendly, neighborhood spider? Spider webs make for an excellent natural treatment for healing cuts and scrapes! This is a long-forgotten natural remedy for sealing open wounds and accelerating healing. Even modern science has embraced spider web as a great treatment for scrapes and wounds.
Spider webs are incredibly strong. It’s made from silk produced from the body proteins of the spider, turning it into silk through spinnerets. The spinnerets are located on a spider’s abdomen. Each spider has three or four spinnerets. Inside the spinnerets are numerous spigots connected to a single silk gland.
The spider silk starts out in liquid form. As the material is being drawn out of the spider’s body, it begins to harden. This movement literally changes the structural components of the protein.
The spider silk could be stronger than a thread of steel in equal thickness yet it’s extremely flexible; so flexible that a spider can spin different patterns without breaking the material. And this is why, surprisingly, it serves a lot of purpose!
How Spider Webs Work to Heal Wounds
Using cobwebs or spider webs has been done since ancient times when Greeks and Romans treated wounded soldiers with it to stop bleeding. Although Greeks and Romans know very little about viral and bacterial infections, through trial and error, they discovered the surprising benefits of spider webs. Soldiers would even use a combination of honey and vinegar to clean deep wounds and then cover the whole thing with balled-up spider webs.
An open wound treated with a cluster of spider web or cobwebs will dry out faster. Cobwebs have antifungal and antiseptic properties that keep bacteria away, minimizing the chances of an infection. It works so well that cobwebs efficiently stop bleeding. What’s more, spider webs are high in vitamin K, a vitamin that triggers blood clotting! As long as the web is clean, it will not cause any infection or aggravate the wound’s condition at all.
How to Make Your Own Bandage Made from Spider Web
WARNING: Do not attempt to make your own spider web bandage when you live in a place full of poisonous spiders.
It’s easy to make your own bandage. First, you have to look for a clean spider web — you want a freshly spun web or one that does not have insect corpse in there. If the spider’s in there, remove the little critter carefully and harvest the web.
Then, ball up the spider web and stuff it onto the wound. Make sure all edges are covered by the web. The web has to touch the surface of the wound. Get a sterile cloth and cover the wound with it. This helps secure the web on the wound while also protecting the affected area from the elements. And there you have it, your own bandage made from spider web.
If the spider web has hardened on your wound and it’s hard to remove, just run your wound over warm water. The water will loosen the web, making it easier to remove.
"He is there for a reason" ;)
You are getting in at a good time!!!
I liked that one vac.
Thanks 907
Does anyone know the average pps from September 1 2010 to today?
Got to love grandma.
;)
hahahahaha
Good one!!!
YEPPER!!
Things are getting interesting.
Long term holders are doing a gut check now.
Some think they should cut their losses, lick their wounds and call it a tax break.
They are panicked and too far out of their comfort zone to logically and rationally look to the future. Historically speaking the share price low has been about double what it is now when in the low dips. It's time for the aggregate body of KBLB investors to convulsively shed the short sighted. Others will hold on tight though this "white knuckled ride" and those who will become rich will consolidate. There is blood in the streets. What will you do? I'll pick up some more cheep ones and wait for commercialization, news on Big Red and other lab achievements as well as the MS roll out.
Good question.
I like the design. My house is a solar passive building.